Current evidence for aripiprazole as augmentation therapy in major depressive disorder

Expert Review of Neurotherapeutics

Volumn 8, Issue 10, 2008, Pages 1435-1447

  Khan, Arif ^a,b  

^a Northwest Clinical Research Center   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Aripiprazole; Major depressive disorder; Remission; Response

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BUSPIRONE; CITALOPRAM; ESCITALOPRAM; FLUOXETINE; LIOTHYRONINE; LITHIUM; MIRTAZAPINE; NEFAZODONE; NORTRIPTYLINE; OLANZAPINE; PAROXETINE; PLACEBO; QUETIAPINE; RISPERIDONE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROIC ACID; VENLAFAXINE; ZIPRASIDONE;

ABNORMAL SENSATION; ADJUVANT THERAPY; AGITATION; AKATHISIA; ANXIETY; APPETITE; ASTHENIA; ATAXIA; BIPOLAR DISORDER; BIPOLAR I DISORDER; BLURRED VISION; BRUXISM; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONCENTRATION LOSS; CONSTIPATION; CONTROLLED CLINICAL TRIAL; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; FEVER; GASTROINTESTINAL SYMPTOM; HAND TREMOR; HEADACHE; HEART PALPITATION; HUMAN; INSOMNIA; JITTERY FEELING; LETHARGY; MAJOR DEPRESSION; MANIA; MEMORY DISORDER; MONOTHERAPY; NAUSEA; NERVOUSNESS; NEUROLEPTIC MALIGNANT SYNDROME; PERIPHERAL EDEMA; RANDOMIZED CONTROLLED TRIAL; REMISSION; RESTLESSNESS; REVIEW; RIGIDITY; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; SUICIDAL IDEATION; SUSTAINED DRUG RELEASE; TARDIVE DYSKINESIA; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE; TREMOR; UPPER RESPIRATORY TRACT INFECTION; URINARY FREQUENCY; WEIGHT GAIN; XEROSTOMIA;

ANTIPSYCHOTIC AGENTS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; DEPRESSIVE DISORDER, MAJOR; DOSE-RESPONSE RELATIONSHIP, DRUG; EVIDENCE-BASED MEDICINE; HUMANS; PIPERAZINES; QUINOLONES; TREATMENT OUTCOME;

EID: 54249108423     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.8.10.1435     Document Type: Review

References (64)

1. Kessler RC, Berglund P, Demler O et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 289, 3095-3105 (2003).
2. Hasin DS, Goodwin RD, Stinson FS, Grant BF. Epidemiology of major depressive disorder: results from the National Epidemiologic Survey on Alcoholism and Related Conditions. Arch. Gen. Psychiatr. 62, 1097-1106 (2005).
3. Ustün TB, Ayuso-Mateos JL, Chatterji S, Mathers C, Murray CJ. Global burden of depressive disorders in the year 2000. Br. J. Psychiatry 184, 386-392 (2004).
4. Fava M, Davidson, KG. Definition and epidemiology of treatment-resistant depression. Psychiatr. Clin. North Am. 19, 179-200 (1996).
5. Frank E, Karp J, Rush AJ. Efficacy of treatments for major depression. Psychopharmacol. Bull. 29, 457-494 (1993).
6. Keller MB, Shapiro RW, Lavori PW, Wolfe N. Recovery in major depressive disorder: analysis with the life table and regression models. Arch. Gen. Psychiatry 39, 905-910 (1982).
7. Scott J. Chronic depression. Br. J. Psychiatry 153, 287-297 (1988).
8. Thase ME. What role do atypical antipsychotic drugs have in treatment-resistant depression? J. Clin. Psychiatry 63, 95-103 (2002).
9. Judd LL, Akiskal HS, Maser JD et al. Major depressive disorder: a prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse. J. Affect. Disord. 50, 97-108 (1998).
10. Van Londen L, Molenaar RP, Goekoop JG, Zwinderman AH, Rooijmans HG. Three to 5-year prospective follow-up of outcome in major depression. Psychol. Med. 28, 731-735 (1998).
11. Paykel ES, Ramana R, Cooper Z, Hayhurst H, Kerr J, Barocka A. Residual symptoms after partial remission: an important outcome in depression. Psychol. Med. 25, 1171-1180 (1995).
12. Thase ME, Simons AD, McGeary J et al. Relapse after cognitive behavior therapy of depression: potential implications for longer courses of treatment. Am. J. Psychiatry 149, 1046-1052 (1992).
13. Miller IW, Keitner GI, Schatzberg AF et al. The treatment of chronic depression, part 3: psychosocial functioning before and after treatment with sertraline or imipramine. J. Clin. Psychiatry 59, 608-619 (1998).
14. Judd LL, Paulus MJ, Schettler PJ et al. Does incomplete recovery from first lifetime major depressive episode herald a chronic course of illness? Am. J. Psychiatry 157, 1501-1504 (2000).
15. Thase ME, Evaluating antidepressant therapies: remission as the optimal outcome. J. Clin. Psychiatry 64(Suppl. 13), 18-25 (2003).
16. Zajecka JM. Treating depression to remission. J. Clin. Psychiatry 64(Suppl. 15), 7-12 (2003).
17. Trivedi MH, Rush AJ, Wisniewski SR et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am. J. Psychiatry 163, 28-40 (2006). •• Describes remission and response rates for citalopram monotherapy in the S Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial.
18. Rush AJ, Trivedi MH, Wisniewski SR et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am. J. Psychiatry 163, 1905-1917 (2006). •• Detailed description of treatment steps and acute and long-term outcomes from the individual levels in the STAR*D trial.
19. Trivedi MH, Fava M, Wisniewski SR et al. Medication augmentation after the failure of SSRIs for depression. N. Engl. J. Med. 354, 1243-1252 (2006). •• Describes STAR*D results for bupropion and buspirone augmentation of citalopram therapy.
20. Lam RW, Hossie H, Solomons K, Yatham LN. Citalopram and bupropion-SR: combining versus switching in patients with treatment-resistant depression. J. Clin. Psychiatry 65, 337-340 (2004).
21. Dé Montigny C, Grunberg F, Mayer A, Deschenes JP. Lithium induces rapid relief of depression in tricyclic antidepressant drug non-responders. Br. J. Psychiatry 138, 252-256 (1981).
22. Nierenberg AA, Fava M, Trivedi MH, Wisniewski SR. A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report. Am. J. Psychiatry 163, 1519-1530 (2006).
23. Bauer M, Dopfmer S. Lithium augmentation in treatment-resistant depression: meta-analysis of placebo-controlled studies. J. Clin. Psychopharmacol. 19, 427-434 (1999).
24. Bauer M, Bschor T, Kunz D. Double-blind, placebo-controlled trial of the use of lithium to augment antidepressant medication in continuation treatment of unipolar major depression. Am. J. Psychiatry 157, 1429-1435 (2000).
25. Aronson R, Offman HJ, Joffe RT, Naylor CD. Triiodothyronine augmentation in the treatment of refractory depression. A meta-analysis. Arch. Gen. Psychiatry 53, 842-848 (1996).
26. Altshuler LL, Bauer M, Frye MA et al. Does thyroid supplementation accelerate tricyclic antidepressant response? A review and meta-analysis of the literature. Am. J. Psychiatry 158, 1617-1622 (2001).
27. Barowsky J, Schwartz TL. An evidence-based approach to augmentation and combination strategies for treatment-resistant depression. Psychiatry 3, 42-61 (2006). • Describes various augmentation strategies for treatment-resistant depression.
28. Carvalho AF, Cavalcante JL, Castelo MS, Lima MCO. Augmentation strategies for treatment-resistant depression: a literature review. J. Clin. Pharm. Ther. 32(5), 415-428 (2007). • Describes various augmentation strategies for treatment-resistant depression.
29. Shelton RC, Tollefson GD, Tohen M et al. A novel augmentation strategy for treating resistant major depression. Am. J. Psychiatry 158, 131-134 (2001).
30. Shelton RC, Williamson DJ, Corya SA et al. Olanzapine/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance. J. Clin. Psychiatry 66, 1289-1297 (2005).
31. Thase ME, Corya SA, Osuntokun O et al. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment resistant major depressive disorder. J. Clin. Psychiatry 68, 224-236 (2007).
32. Corya SA, Williamson D, Sanger TM, Briggs SD, Case M, Tollefson G. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression. Depress. Anxiety 23, 364-372 (2006).
33. McIntyre A, Gendron A, McIntyre A. Quetiapine adjunct to selective serotonin reuptake inhibitors or venlafaxine in patients with major depression, comorbid anxiety, and residual depressive symptoms: a randomized, placebo-controlled pilot study. Depress. Anxiety 24, 487-494 (2007).
34. Dorée JP, Des Rosiers J, Lew V et al. Quetiapine augmentation of treatmentresistant depression: a comparison with lithium. Curr. Med. Res. Opin. 23, 333-341 (2007).
35. Ostroff RB, Nelson JC. Risperidone augmentation of selective serotonin reuptake inhibitors in major depression. J. Clin. Psychiatry 60, 256-259 (1999).
36. Mahmoud RA, Pandina GJ, Turkoz I et al. Risperidone for treatment-refractory major depressive disorder: a randomized trial. Ann. Intern. Med. 147, 593-602 (2007).
37. Papakostas GI, Petersen TJ, Nierenberg AA et al. Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant major depressive disorder. J. Clin. Psychiatry 65, 217-221 (2004).
38. Abilify®, prescribing information. Bristol-Myers Squibb Company, Otsuka America Pharmaceutical, Inc. USA (2007).
39. A, Renock S, Arrington E et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 28, 1400-1411 (2003). •• Presents a comprehensive summary of the pharmacology of aripiprazole.
40. Zangen A, Nakash R, Overstreet DH, Yadid G. Association between depressive behavior and absence of serotonin-dopamine interaction in the nucleus aaccumbens. Psychopharmacol. 155, 434-439 (2001).
41. 1A receptor. Eur. J. Pharmacol. 441, 137-140 (2002).
42. Glennon RA, Dukat M. Serotonin receptor subtypes. In: Pharmacology: The Fourth Generation Of Progress. Bloom FE, Kupfer DJ (Eds). Raven Press, NY, (1995).
43. Scott JA, Crews FT. Down-regulation of serotonin 2, but not of β-adrenergic receptors during chronic treatment with amitriptyline is independent of stimulation of serotonin 2 and β-adrenergic receptors. Neuropharmacology 25, 1301-1306 (1986).
44. Chew ML, Mulsant BH, Pollock BG, Lehman ME et al. A model of anticholinergic activity of atypical antipsychotic medications. Schizophr. Res. 88, 63-72 (2006).
45. Fava M. Augmentation and combination strategies in treatment-resistant depression. J. Clin. Psychiatry 62(Suppl. 18), 4-11 (2001). • Describes augmentation strategies in treatment-resistant depression.
46. Blier P, Szabo ST. Potential mechanisms of action of atypical antipsychotic medications in treatment-resistant depression and anxiety. J. Clin. Psychiatry 66(Suppl. 8), 30-40 (2005).
47. Bortolozzi A, Diaz-Mataix L, Toth M, Celada P, Artigas F. In vivo actions of aripiprazole on serotonergic and dopaminergic systems in rodent brain. Psychopharmacology 191, 745-758 (2007).
48. Pae C, Serretti A, Patkar AA, Masand PS. Aripiprazole in the treatment of depressive and anxiety disorders: a review of current evidence. CNS Drugs 22(5), 367-388 (2008). • Describing the mechanism of action and clinical data for aripiprazole in major depressive disorder (MDD).
49. 2/3 receptor binding in major depression. Psychiatry Clin. Neurosci. 62, 345-348 (2008).
50. Adson DE, Kushner MG, Fahnhorst TA. Treatment of residual anxiety symptoms with adjunctive aripiprazole in depressed patients taking selective serotonin reuptake inhibitors. J. Affect. Disord. 86, 99-104 (2005).
51. Papakostas GI, Petersen TJ, Kinrys G et al. Aripiprazole augmentation of selective serotonin reuptake inhibitors for treatment-resistant major depressive disorder. J. Clin. Psychiatry 66, 1326-1330 (2005).
52. Pae C, Patkar AA, Jun T et al. Aripiprazole augmentation for treatment of patients with inadequate antidepressants response. Depress. Anxiety 24, 522-526 (2007).
53. Simon JS and Nemeroff CB. Aripiprazole augmentation of antidepressants for the treatment of partially responding and nonresponding patients with major depressive disorder. J. Clin. Psychiatry 66, 1216-1220 (2005).
54. Rutherford B, Sneed J, Miyazaki M et al. An open trial of aripiprazole augmentation for SSRI non-remitters with late-life depression. Int. J. Geriatr. Psychiatry 22, 986-991 (2007).
55. Patkar AA, Peindl K, Mago R et al. An open-label, rater-blinded, augmentation study of aripiprazole in treatment-resistant depression. Prim. Care Companion J. Clin. Psychiatry 8, 82-87 (2006).
56. Hellerstein DJ, Batchelder S, Hyler S et al. Aripiprazole as an adjunctive treatment for refractory unipolar depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 32, 744-750 (2008).
57. Schule C, Baghai TC, Eser D et al. Mirtazapine monotherapy versus combination therapy with mirtazapine and aripiprazole in depressed patients without psychotic features: a 4-week open-label parallel-group study. World J. Biol. Psychiatry 8, 112-122 (2007).
58. Barbee JG, Conrad EJ, Jamhour NJ. Aripiprazole augmentation in treatment-resistant depression. Ann. Clin. Psychiatry 16, 189-194 (2004).
59. Worthington JJ 3rd, Kinrys G, Wygant LE, Pollack MH. Aripiprazole as an augmentor of selective serotonin reuptake inhibitors in depression and anxiety disorder patients. Int. Clin. Psychopharmacol. 20, 9-11 (2005).
60. Berman RM, Marcus RN, Swanink R et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J. Clin. Psychiatry 68, 843-853 (2007). •• Publication of first multicenter, double-blind, randomized, placebo-controlled trial for aripiprazole as augmentation therapy in MDD.
61. Marcus RN, McQuade RD, Carson WH et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. J. Clin. Psychopharmacol. 28, 156-165 (2008). •• Publication of second multicenter, double-blind, randomized, placebo-controlled trial for aripiprazole as augmentation therapy in MDD.
62. Thase ME, Jonas A, Khan A et al. Aripiprazole monotherapy in non-psychotic bipolar I depression. Results of 2 randomized, placebo-controlled studies. J. Clin. Psychopharmacol. 28, 12-20 (2008).
63. Miller DD, Eudicone JM, Pikalov A, Kim E. Comparative assessment of the incidence and severity of tardive dyskinesia in patients receiving aripiprazole or haloperidol for the treatment of schizophrenia: a post hoc analysis. J. Clin. Psychiatry 68, 1901-1906 (2007).
64. Phychiatry online www.psychiatryonline.com